Want to see AMS full AI Analyst Report?
American Shared Hospital Services (AMS) AI Stock Analysis
American Shared Hospital Services
(NYSE MKT:AMS)
AMS scores in the low-to-mid range primarily due to still-weak profitability and historical volatility despite improved TTM cash generation and reduced leverage. Technicals are broadly neutral with only modest momentum and a weaker longer-term trend versus the 200-day average. Valuation provides limited support given the negative P/E and no dividend, while the earnings call showed improving operations and liquidity that are tempered by continued capital-structure and refinancing risk.
American Shared Hospital Services (AMS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.31M
- Dividend Yield
- ―
- Average Volume (3M)
- 11.10K
- Price to Earnings (P/E)
- -4.9
- Beta (1Y)
- 0.30
- Revenue Growth
- 3.97%
- EPS Growth
- 28.88%
- Country
- US
- Employees
- 83
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
American Shared Hospital Services Business Overview & Revenue Model
Company Description
American Shared Hospital Services specializes in leasing advanced radiosurgery and radiation therapy equipment to healthcare providers. The company offers Gamma Knife stereotactic radiosurgery systems, a non-invasive technology used to treat conditio...
How the Company Makes Money
AMS primarily makes money by enabling hospitals and treatment centers to provide advanced radiation therapy without those providers bearing the full upfront burden of owning and operating the technology. Its revenue model typically centers on long-te...
American Shared Hospital Services Earnings Call Summary
The call communicated clear operational progress: double‑digit revenue growth, strong expansion of direct patient services (≈+40% Q2), meaningful proton therapy growth (~+22%), international throughput gains after technology upgrades, and robust cash generation (operating cash flow $4.4M YTD; cash up >80% vs year‑end). These positives are tempered by near‑term balance sheet and earnings noise: a $909K receivable allowance, $285K legal costs, a YoY Q2 adjusted EBITDA decline (from $1.7M to $1.3M), and an amended loan with potential sale provisions and refinancing risk ( ~$15.5M due by June 2027). Overall, operational momentum and improved liquidity/supporting financing actions outweigh the balance‑sheet and one‑time challenges, though capital structure risk remains the primary area of concern.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management's guidance focused on three clear priorities—drive sustainable revenue growth by increasing utilization and expanding the installed base, convert that revenue into improved profitability and operating cash flow, and strengthen the balance sheet—supported by the quarter's metrics: Q2 revenue ~ $8.4M (+19.2% YoY) and H1 revenue > $15.5M (+17.7%); Direct Patient Services Q2 revenue ~ $4.9M (+~40%) and H1 ~ $8.9M (+35%); Proton beam revenue Q2 ~ $2.3M (+22%) and H1 ~ $4.3M; gross margin ~ $1.4M; adjusted EBITDA Q2 ~ $1.3M (YTD ~ $2.5M; prior-year Q2 ~$1.7M); operating cash flow of $4.4M in H1 and cash of ~ $6.8M at quarter end (up >80% since the start of the year from $3.7M at YE2025); offsetting items included a $909k allowance for credit losses and $285k of legal/professional costs, with post-quarter support from $2M of subordinated financing and a Fifth Third amendment extending loan maturity to 6/30/2027 on roughly $15.5M of outstanding debt (potentially ~$13.3M after adjustments) while management pursues refinancing or other strategic options.
American Shared Hospital Services Financial Statement Overview
Summary
Financials are mixed: TTM revenue rose sharply, and TTM operating cash flow (~$5.4M) and free cash flow (~$3.5M) turned positive, with leverage improved in TTM (debt/equity ~0.18x). However, profitability remains the key weakness with negative operating profit and net income (net margin ~-5.8%) and notable year-to-year volatility, indicating earnings consistency is not yet proven.
Income Statement
42NeutralBalance Sheet
63PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.41M | 28.08M | 28.34M | 21.32M | 19.75M | 17.63M |
| Gross Profit | 5.20M | 5.04M | 9.19M | 9.34M | 8.38M | 6.73M |
| EBITDA | 3.10M | 4.07M | 8.91M | 6.97M | 8.11M | 6.97M |
| Net Income | -1.77M | -1.55M | 2.19M | 610.00K | 1.33M | 194.00K |
Balance Sheet | ||||||
| Total Assets | 52.49M | 55.48M | 60.20M | 48.16M | 43.96M | 45.43M |
| Cash, Cash Equivalents and Short-Term Investments | 6.51M | 3.46M | 11.03M | 13.69M | 12.34M | 8.14M |
| Total Debt | 20.52M | 22.61M | 23.23M | 17.64M | 14.31M | 17.47M |
| Total Liabilities | 26.68M | 27.79M | 30.17M | 21.88M | 18.33M | 21.19M |
| Stockholders Equity | 23.11M | 24.03M | 25.18M | 22.62M | 21.63M | 19.89M |
Cash Flow | ||||||
| Free Cash Flow | 3.54M | -4.54M | -7.77M | -555.00K | 6.85M | 4.59M |
| Operating Cash Flow | 5.35M | 3.10M | 167.00K | 5.72M | 7.24M | 6.27M |
| Investing Cash Flow | -1.82M | -7.63M | -7.11M | -6.27M | -388.00K | -1.67M |
| Financing Cash Flow | -8.11M | -3.03M | 4.41M | 1.91M | -2.66M | -655.00K |
American Shared Hospital Services Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMS, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.38, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 39.36 is Neutral, neither overbought nor oversold. The STOCH value of 30.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMS.
American Shared Hospital Services Risk Analysis
American Shared Hospital Services disclosed 25 risk factors in its most recent earnings report. American Shared Hospital Services reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksAmerican Shared Hospital Services Peers Comparison
Overall Rating
PACS74Outperform
SGRY59Neutral
ARDT56Neutral- AMS53Neutral
CYH42Neutral
CCM40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PACS | 74Outperform | $7.57B | 26.81 | 27.15% | ― | 15.15% | 101.51% |
| SGRY | 59Neutral | $2.99B | -33.51 | -5.21% | ― | 3.99% | 51.58% |
| ARDT | 56Neutral | $1.70B | 21.33 | 5.21% | ― | 3.34% | -69.26% |
| AMS | 53Neutral | $8.45M | -4.95 | -7.45% | ― | 3.97% | 28.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CYH | 42Neutral | $338.46M | -0.54 | 36.02% | ― | -7.84% | -88.93% |
| CCM | 40Underperform | $15.50M | -0.03 | 5.16% | ― | 20.26% | 69.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AMS | American Shared Hospital Services | 1.25 | -0.85 | -40.56% | |
| CYH | Community Health Systems | 2.10 | -1.68 | -44.44% | |
| CCM | Concord Medical Services | 3.59 | -1.67 | -31.75% | |
| SGRY | Surgery Partners Inc. | 23.12 | 1.12 | 5.09% | |
| PACS | PACS Group Inc | 45.58 | 33.12 | 265.81% | |
| ARDT | Ardent Health Partners, Inc. | 11.73 | -2.83 | -19.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026